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Corepressor N-CoR (nuclear receptor corepressor) and the highly related protein SMRT (silencing mediator
of retinoid and thyroid hormone receptor) play important roles in different biological processes including
proliferation, differentiation, and development. Understanding the biological function of these corepressors
requires identification and characterization of their interacting proteins. Here we report the characterization
of a novel N-CoR-interacting protein, JMJD2A (previously known as KIAA0677). JMJD2A is an evolutionarily
conserved nuclear protein containing many functionally unknown domains. JMJD2A directly interacts with the
N-terminal region of N-CoR through a small NID (N-CoR interaction domain) both in vitro and in vivo.
Despite its copurification with N-CoR, JMJD2A is not a core subunit of the stable multiprotein N-CoR complex
and is not required for N-CoR-mediated repression by thyroid hormone receptor. By chromatin immunopre-
cipitation cloning, we identified the human achaete scute-like homologue 2 (ASCL2/Hash2) gene as a gene
regulated by JMJD2A. ASCL2 is a basic helix-loop-helix transcription factor whose mouse homolog is encoded
by an imprinted gene highly expressed during the development of extraembroynic trophoblast lineages but
repressed in other tissues and is essential for proper placental development. We demonstrated that JMJD2A
selectively represses the expression of the ASCL2 gene but not other imprinted genes in the same imprinted
locus in HeLa cells and that this repression required a functional N-CoR complex and the tandem Tudor
domain of JMJD2A. Like N-CoR, JMJD2A is widely expressed in various mouse tissues. Our data indicate that
JMJD2A makes use of the N-CoR complex to repress transcription and suggest that JMJD2A together with
N-CoR could play a role in repressing ASCL2 expression in various tissues.
In eukaryotic cells, DNA is wrapped around histone octam-
ers that consist of two molecules of each of the core histones
H2A, H2B, H3, and H4 to form chromatin. Although chroma-
tin was once considered to serve only as a structural compo-
nent for the storage of genomic information, it is now widely
accepted that chromatin also plays essential roles in the regu-
lation of multiple processes including DNA replication, tran-
scription, and repair (2, 8, 47, 49). Numerous proteins and
protein complexes regulate transcription by posttranslationally
modifying histones. These modifications include acetylation,
methylation, phosphorylation, ubiquitylation, and sumoylation
(2, 39, 54). It is well established that increased histone acety-
lation generally correlates with transcription activation and
that deacetylation correlates with repression. Although the
precise mechanism that links acetylation to transcriptional reg-
ulation is still not fully understood, histone acetylation cata-
lyzed by histone acetyltransferases are thought to weaken
DNA/histone interactions and affect higher-order chromatin
folding to modulate the accessibility of promoter sequences to
transcription factors and basal transcriptional machinery (12,
36). In addition, histone acetylation can serve as a specific code
for binding of transcriptional regulatory proteins (40, 42). On
the other hand, histone deacetylation catalyzed by HDACs
(histone deacetylases) antagonizes acetyltransferase activity
and favors the tight compaction of the histone-DNA complex.
Numerous HDAC-containing repression complexes have
been identified (3, 4, 9, 11, 48). Among them are N-CoR
(nuclear receptor corepressor) and SMRT (silencing mediator
for retinoid and thyroid hormone receptor) complexes. SMRT
and N-CoR are two highly related proteins originally isolated
and characterized by their ability to interact with the unligan-
ded forms of nuclear hormone receptors and confer transcrip-
tional repression (18, 34, 35). Recent studies have implicated
N-CoR and SMRT in repression by diverse transcription fac-
tors including Mad/Mxi, BCL6/LAZ3, ETO, CBF, and REST/
NRSF (7, 11, 22, 23, 32, 33, 43, 44). Mouse N-CoR is required
for early embryonic development, and N-CoR null mice show
defects in neural cell differentiation and developmental pro-
gression of specific erythrocytes and thymocytes (17, 21). To
understand the mechanism by which SMRT and N-CoR me-
diate transcriptional repression, several groups have attempted
isolation and characterization of steady-state SMRT and N-
CoR complexes. These efforts collectively demonstrate that
both SMRT and N-CoR exist in large protein complexes with
an estimated size of 1.5 to 2 MDa and are primarily associated
with TBL1 and TBLR1, two highly related WD-40 repeat pro-
teins, GPS2, a cellular signaling protein, and HDAC3 (13, 27,
50, 51, 53). As these proteins appear to stably associate with
SMRT and N-CoR in stoichiometric levels (13, 27, 50, 53), they
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can be viewed as the core subunits of SMRT and N-CoR
complexes. Consistent with this idea, recent studies indicate
that HDAC3 is required for SMRT/N-CoR-mediated repres-
sion by unliganded thyroid hormone receptor (TR) (20, 50),
whereas TBL1 and TBLR1 are redundantly essential for this
process (52).
In addition to the aforementioned core subunits, the diverse
functions of SMRT and N-CoR are likely to be carried out by
other proteins that interact transiently and/or differentially
with SMRT and N-CoR. In this study, we have characterized a
novel protein, KIAA0677, which was copurified with N-CoR
(51). KIAA0677 is a highly evolutionally conserved protein
containing several interesting domains including a Jumonji do-
main (JmjN) and a related JmjC domain, a PHD domain, and
a tandem Tudor domain (Fig. 1A) (24). Although the function
of these domains is not clear, the proteins harboring these
domains have often been implicated in transcriptional regula-
tion. Due to the presence of the JmjN and JmjC domains, this
protein was recently renamed JMJD2A, a member of the pro-
posed JMJD2 family proteins (24). We show here that
JMJD2A physically interacts with N-CoR but is not a core
subunit of the N-CoR complex. We identified the human
achaete-scute homolog 2 (ASCL2, also called Hash2) gene,
encoding a basic helix-loop-helix (bHLH) transcription factor,
as a target gene repressed by JMJD2A. Mouse ASCL2, also
called Mash2, is a transcriptional factor essential for placental
development. Mash2/ embryos die from placental failure at
10 days postcoitum (15). The ASCL2 gene has been mapped to
human chromosome 11p15.5, a region containing a cluster of
imprinted genes, including the insulin-2, insulin-like growth
factor 2, and H19 genes (1, 14). We provide evidence that
JMJD2A is specifically involved in the repression of the
ASCL2 gene and does not appear to affect the transcriptional
activity of the other genes in this imprinted region. Further-
more, this repression requires a functional N-CoR complex,
suggesting a working model in which JMJD2A targets the
N-CoR complex to repress ASCL2 gene expression. Our data
also suggest that JMJD2A and N-CoR may be involved in the
regulation of fetoplacental development through repression of
ASCL2.
MATERIALS AND METHODS
Preparation of whole-cell lysates and immunoprecipitation. HeLa cells were
washed with phosphate-buffered saline (PBS) two times and lysed with EBC
buffer (20 mM Tris-HCl, pH 8.0, 125 mM NaCl, 2 mM EDTA, and 0.5% NP-40)
with protease inhibitors. After removing cell debris by high-speed centrifugation,
cell lysates were precleared with protein A-conjugated Sepharose beads for 2 h
at 4°C with gentle agitation. Then specific antibodies were added and incubated
overnight at 4°C with rotation. Immunoprecipitation was done by adding protein
A-conjugated Sepharose beads and incubating at 4°C for another 2 h with
rotation. Beads were washed five times with EBC buffer, 10 min each. Sodium
dodecyl sulfate (SDS) buffer (2) was added directly to the beads and boiled for
5 min before samples were loaded and separated by 7.5% SDS-polyacrylamide
gel electrophoresis (PAGE). For multiple rounds of blotting, the membranes
were stripped in stripping buffer (100 mM -mercaptolethanol, 2% SDS, and
62.5 Tris-Cl, pH 6.7) for 30 min at 50°C.
Northern blot and immunostaining. The nylon membrane with mRNA from
different mouse tissues was purchased from Ambion Inc. (Austin, TX) and
probed with 32P-labeled specific probes (amplified by reverse transcription-PCR
[RT-PCR]) against either mouse JMJD2A, N-CoR, or GAPDH (glyceraldehyde-
3-phosphate dehydrogenase) according to the manufacturer’s instructions. For
immunostaining, cells were grown on glass cover slides overnight and fixed with
3.5% formaldehyde for 15 min. Then, cells were permeabilized with 0.02%
NP-40 for 1 min and blocked with 5% goat serum for 1 h. Next, cells were
incubated with the anti-JMJD2A-specific antibody for 2 h, followed by a second-
ary donkey anti-rabbit immunoglobulin G (IgG) conjugated with Alexa Fluor 594
for 2 h. Images were visualized by conventional microscopy.
Plasmids and transient transfection. The various N-CoR constructs used for
the in vitro transcription/translation reaction were as described previously (27,
50), and the SMRTe construct (35) was kindly provided by Don Chen (University
of Massachusetts). The DNA constructs used in the Gal4 fusions were made by
cloning amplified PCR products into modified pCMX-Gal mammalian expres-
sion vectors. Inverse PCR was used to generate different JMJD2A deletions. For
glutathione S-transferase (GST) pull-down, the DNA encoding the peptide (597
to 720 amino acids) that contains the N-CoR binding domain of JMJD2A was
amplified by RT-PCR and cloned into pGEX-4T (Pharmacia), creating an in-
frame fusion to GST. The same GST fusion peptide was used for the generation
of polyclonal anti-JMJD2A antibodies. To generate the ASCL2P-luc reporter,
the DNA fragment corresponding to 1523 to 1 of the ASCL2 promoter was
PCR amplified and cloned into the pGL3-basic reporter. The various ASCL2
FIG. 1. JMJD2A interacts with N-CoR but is unlikely to be a core
subunit of the N-CoR complex. (A) Diagram showing the structural
organization of the 1,064-amino-acid JMJD2A protein. The JmjN,
JmjC, PHD, and tandem Tudor domains are indicated. (B) Reciprocal
coimmunoprecipitation of JMJD2A and N-CoR from HeLa nuclear
extracts. The immunoprecipitation (IP) and Western blotting (WB)
were as indicated. For a control, IP with rabbit anti-mouse IgG was
used. (C) Transiently expressed FLAG-tagged JMJD2A (F-JMJD2A)
also coimmunoprecipitated with N-CoR. (D) A small fraction of
JMJD2A cofractionated with N-CoR in a gel filtration experiment.
HeLa cell nuclear extracts were passed through a Superose 6 column,
and different fractions were collected and resolved by 7.5% SDS-
PAGE. Western blots were conducted with either anti-JMJD2A or
anti-N-CoR antibodies as indicated. The peak fractions for molecular
weight markers were as indicated. (E) Northern analysis showing the
expression of JMJD2A and N-CoR in various mouse tissues. The levels
of GADPH mRNA served as a loading control.
VOL. 25, 2005 JMJD2A REPRESSES ASCL2/Hash2 EXPRESSION THROUGH N-CoR 6405
promoter deletion mutants were constructed through PCR based on ASCL2P-
Luc. All constructs were verified by sequencing. Transient transfections of DNA
were done using Lipofectamine 2000 according to the manufacturer’s instruc-
tions (Invitrogen Inc.). Most of the transient-transfection experiments were per-
formed with triplicates and repeated at least three times.
GST pull-down assay. GST pull-down assays were done as previously de-
scribed (50). Both GST and GST-JMJD2A (597-720) fusion proteins were ex-
pressed in BL21 Escherichia coli cells, and equal amounts of each protein were
immobilized onto glutathione-Sepharose beads. The beads were incubated over-
night with 35S-labeled SMRT, N-CoR, other proteins, or N-CoR fragments
synthesized using a TNT in vitro transcription/translation kit (Promega) accord-
ing to the manufacturer’s instruction. The beads were washed five times with
washing buffer (10 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 0.1% NP-40 with
protease inhibitors). The samples were then separated by SDS-PAGE and visu-
alized by autoradiography.
Cell culture and siRNA. HeLa cells were routinely maintained in Dulbecco’s
modified Eagle medium (Invitrogen Inc.) supplemented with 10% fetal bovine
serum and 1% antibiotics at 37°C under 5% CO2. For the small interference
RNA (siRNA) experiments, HeLa cells were seeded the night before transfec-
tion at such a density that cells reach about 30 to 40% confluence by the time of
transfection. The siRNAs against N-CoR and HDAC3 were previously described
(50). The siRNA against JMJD2A was the combination of two siRNAs synthe-
sized by Dharmacon Research: siJMJD2-I (AACACAGUUAUUGACCAU
ACU) and JMJD2A-II (AAGUUGAGGAUGGUCUUACCU). A combination
of 20 nM of each siJMJD2A was used for transfection using Lipofectamine 2000
(Invitrogen) according to the manufacturer’s instructions. Transfected cells were
continued in culture for 3 days before harvesting for further analyses. The
efficiency of the siRNA knockdown was determined by Western analysis using
corresponding specific antibodies.
Total RNA extraction and RT-PCR. Total RNA from cultured cells was pu-
rified using the RNeasy kit (QIAGEN) according to the manufacturer’s instruc-
tions. All RNA extracts were treated with RNase-free DNase to eliminate
genomic DNA contamination. RT-PCR was conducted using a QIAGEN kit.
Primers for the ASCL2 amplification were 5-AGCCCGGCTCCCCGCGTTCC
GCCTACT-3 and 5-TAGCCCCCTAACCAGCTGGAGAAGTCG-3. Prim-
ers for the GAPDH amplification were 5-ACAGCCTCAAGATCATCAGCAA
and 5-ACCACTGACACGTTGGCAGT-3. Primers for the IGF-2 amplifica-
tion were 5-TGCAGTAGTTCTCCAGCTGGTAGA-3 and 5-AGCCTTTGT
GAACCAACACCTGT-3. PCR products were separated by agarose gel elec-
trophoresis and visualized by ethidium bromide staining.
ChIP and ChIP cloning. Chromatin immunoprecipitation (ChIP) assays were
performed essentially as described previously (51) with the following modifica-
tions. In brief, to detect the association of JMJD2A and N-CoR with the endog-
enous ASCL2 promoter, approximately 2  109 HeLa cells in 150-mm dishes
were treated with 1% formaldehyde in PBS for 10 min at room temperature with
gentle agitation. The cells were rinsed twice with PBS and then incubated in 100
mM Tris-HCl (pH 9.4)–10 mM dithiothreitol (DTT) at 30°C for 15 min. After
centrifugation at 3,000 rpm for 1 min, the cells were rinsed once with cold PBS
and resuspended in 600 l of solution A (10 mM HEPES, pH 7.9, 0.5% NP-40,
1.5 mM MgCl2, 10 mM KCl, and 0.5 mM DTT). The cell lysates were centrifuged
at 3,000 rpm for 5 min, and the supernatant was discarded. The nuclear pellets
were resuspended in solution B (20 mM HEPES, pH 7.9, 25% glycerol, 0.5%
NP-40, 0.42 M NaCl, 1.5 mM MgCl2, 0.2 mM EDTA) containing protease
inhibitors by vigorous pipetting to release nuclear proteins. After centrifugation
at 13,000 rpm for 30 min, the nuclear pellets were resuspended in IP buffer (1%
Triton X-100, 2 mM EDTA, 20 mM Tris-HCl, pH 8.0, 150 mM NaCl with
protease inhibitors) and sonicated to break chromatin into fragments with an
average length of 0.5 to 1.0 kb. ChIP assays were then carried out as described
previously (51) using the antibodies indicated in the figures.
For the identification of JMJD2A target genes, ChIP cloning was first con-
ducted with the JMJD2A antibody essentially as described above. After the final
wash, DNA-protein complexes were eluted twice in 50 l of 10 mM DTT at 37°C
for 10 min. The eluted DNA was combined and diluted 20 with dilution buffer
(2 mM EDTA, 100 mM NaCl, 20 mM Tris-HCl, pH 8.1, and 0.5% Triton X-100).
The N-CoR antibody was added to conduct the second round of ChIP. The resulting
DNA was purified using a Qiaquick kit (QIAGEN Sciences), blunt-ended, cloned,
and sequenced. The 171-bp JAR sequence is available upon request.
RESULTS
Characterization of JMJD2A as an N-CoR-associated pro-
tein. We previously showed that KIAA0677 copurified with
N-CoR (51). Recently, KIAA0677 was categorized as a mem-
ber of the JMJD2 (Jumonji domain-containing 2) family and
named JMJD2A (24). JMJD2A was mapped to human chro-
mosome 1p34.3. The full-length JMJD2A cDNA is more than
4.7 kb, with an open reading frame encoding a protein of 1,064
amino acids.
As a first step to verify that JMJD2A truly interacts with
N-CoR, we raised a JMJD2A-specific antibody against amino
acids 592 to 720 of JMJD2A. HeLa nuclear extracts were first
immunoprecipitated with an N-CoR- or JMJD2A-specific an-
tibody and then analyzed by Western blotting. The result in
Fig. 1B showed that N-CoR coprecipitated with JMJD2A and
vice versa. Under the same condition, a control rabbit anti-
mouse IgG did not precipitate either N-CoR or JMJD2A. To
further confirm the interaction between these two proteins, a
DNA construct encoding FLAG-tagged JMJD2A was trans-
fected into HeLa cells. Whole-cell lysates were prepared from
the transfected cells and used for immunoprecipitation with
antibodies against either FLAG or N-CoR. Again, FLAG-
JMJD2A coimmunoprecipitated with N-CoR (Fig. 1C). To-
gether, these data provide strong evidence that JMJD2A in-
teracts with N-CoR.
To examine the extent to which JMJD2A associates with
N-CoR, HeLa nuclear extract was subjected to gel filtration
analysis using a Superose 6 column and the resulting fractions
were analyzed by Western blotting. Consistent with our previ-
ous data (27), N-CoR migrated as a 1.5- to 2-MDa complex(es)
and peaked between fractions 9 and 11 (Fig. 1D). On the other
hand, only a small fraction of JMJD2A cofractionated with
N-CoR (peak 11) and the majority of JMJD2A existed either
in a very small complex(es) or alone (fractions 17 to 21). This
is unlikely as a result of JMJD2A’s being much more abundant
than N-CoR, since depletion of JMJD2A from HeLa nuclear
extracts could not deplete N-CoR and vice versa (data not
shown). Thus, under our experimental conditions, much of the
cellular JMJD2A protein did not appear to associate with the
N-CoR complex(es), suggesting that JMJD2A is unlikely a
core subunit of the N-CoR complex(es).
Expression patterns of JMJD2A. JMJD2A is not only part of
a newly identified protein family with a few conserved domains
but also shows a high degree of conservation in evolution, with
homologues from yeast to humans (24; our unpublished data).
Somewhat surprisingly, little is known about the functions of
this protein family. Given its conservation in evolution, we
were interested in its expression pattern in mice. A tissue blot
was analyzed by Northern hybridization, and results in Fig. 1E
show that JMJD2A is broadly expressed, although thymus,
ovary, and heart have relatively higher levels of expression.
Noticeably, JMJD2A and N-CoR have similar patterns of ex-
pression, and both are also highly expressed in embryos.
JMJD2A is a nuclear protein and has repression activity.
We next examined the subcellular localization of JMJD2A by
immunostaining. The result (Fig. 2A) showed that in HeLa
cells JMJD2A was detected primarily in nuclei by using our
JMJD2A-specific antibody raised against amino acids 592 to
720 of JMJD2A. In addition, the Flag-tagged JMJD2A tran-
siently expressed in HeLa cells was also found primarily in
nuclei as revealed by immunostaining using a Flag-specific
antibody (data not shown). Together these results indicate that
JMJD2A in HeLa cells is a nuclear protein, consistent with the
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fact that JMJD2A copurified with N-CoR from HeLa nuclear
extracts.
As a nuclear protein that copurified and coimmunoprecipi-
tated with N-CoR (Fig. 1B and 1C), we next tested whether
JMJD2A possesses repression activity when tethered to DNA
through a heterologous DNA binding domain (Gal-DBD). A
luciferase reporter driven by a minimal thymidine kinase (TK)
promoter containing four Gal binding sites (4xUAS) was co-
transfected with either a Gal-DBD or Gal-JMJD2A expression
construct into HeLa cells. After overnight incubation, relative
luciferase activity was measured from the transfected cells. The
results in Fig. 2B showed that Gal-JMJD2A actively repressed
transcription in comparison to the Gal-DBD alone.
To analyze whether the repression by Gal-JMJD2A is re-
lated to the interaction between JMJD2A and N-CoR, we used
ChIP assays to test whether the N-CoR complex was recruited
by JMJD2A to the 4xUAS-TK-luc reporter. For this purpose,
HeLa cells were transfected with the reporter alone or the
reporter plus either the Gal-DBD or Gal-JMJD2A expression
construct. After overnight incubation, the cells were treated
with 1% formaldehyde to cross-link proteins to DNA and
processed for ChIP assay as described in detail in Materials
and Methods. The results in Fig. 2C showed that, while both
Gal-DBD and Gal-JMJD2A bound to the reporter as ex-
pected, N-CoR was detected only in the presence of Gal-
JMJD2A. This result indicates that targeting Gal-JMJD2A to
the reporter resulted in the recruitment of N-CoR. Further-
more, a ChIP assay using a SMRT-specific antibody also re-
vealed the recruitment of SMRT by Gal-JMJD2A. This result
indicates that JMJD2A can interact with both SMRT and
N-CoR. Consistent with the fact that HDAC3 is a core subunit
of the SMRT/N-CoR complexes, HDAC3 was also recruited
by Gal-JMJD2A. Together, these ChIP data provide strong
evidence that JMJD2A associates with SMRT/N-CoR in vivo
and also reveal that JMJD2A is likely to repress transcription
by recruiting the SMRT/N-CoR complex.
JMJD2A interacts with N-CoR through a 41-amino-acid
domain located in the middle of the molecule. The above ChIP
data indicate that tethering JMJD2A to DNA results in re-
cruitment of the N-CoR complex. We next made use of this
ChIP assay to map the N-CoR interaction domain in JMJD2A.
As shown in Fig. 1A, JMJD2A contains the JmjC, JmjN, Tu-
dor, and PHD domains, which are conserved among the
JMJD2 family members (24). To map the N-CoR interaction
domain(s), we first divided the JMJD2A protein into three
fragments, the N-terminal (amino acids 1 to 370), the middle
(amino acids 347 to 720), and the C-terminal (amino acids 680
to 1064) fragments. Each fragment was fused with the Gal4-
DBD, and their ability to recruit N-CoR was analyzed by ChIP
assay. This analysis revealed that the middle portion of
JMJD2A (fragment 347-720) strongly recruited N-CoR (Fig.
3A). Fragment 1-370 could also recruit N-CoR, although it was
at least five times weaker than fragment 347-720 (Fig. 3A). On
the other hand, no detectable recruitment was observed for
fragment 680-1064 (Fig. 3A). Thus, JMJD2A may contain two
N-CoR interaction domains, a weak one in fragment 1-370 and
a strong one in the region between amino acids 347 and 720.
Note that this experiment did not exclude the possibility that
JMJD2A indirectly recruits N-CoR via interaction with other
subunits in the N-CoR complex.
We next focused our attention on further defining the N-
CoR interaction domain within fragment 347-720. A series of
new Gal fusion constructs were generated (Fig. 3E), and ChIP
assays were employed to analyze their ability to recruit N-CoR.
The result in Fig. 3B shows that fragment 597-720 was still
capable of recruiting N-CoR. Further, the experiment in Fig.
3C shows that a 41-amino-acid fragment (597-637) was neces-
sary and sufficient for the recruitment of N-CoR. Most impor-
tantly, the result in Fig. 3D shows that the full-length JMJD2A
deleted of this 41-amino-acid fragment (Gal-597-638) was not
able to recruit N-CoR. As controls, both Gal fusions of full-
length JMJD2A and the 41-amino-acid fragment were able to
recruit N-CoR under the same condition. Thus, in the full-
length context, the 41-amino-acid fragment from 597 to 638 is
necessary for the recruitment of N-CoR, despite the presence
of a weak N-CoR interaction domain in fragment 1-370. Taken
together, we conclude that the 41-amino-acid region from 597
to 638 of JMJD2A is necessary and sufficient for interaction
with N-CoR. The result of these interaction assays is summa-
rized in Fig. 3E.
FIG. 2. JMJD2A is a nuclear protein that possesses transcriptional-
repression activity. (A) Immunostaining revealed that JMJD2A is pri-
marily a nuclear protein in HeLa cells. Also shown is DAPI (4,6-
diamidino-2-phenylindole) staining of nuclei. (B) JMJD2A functioned
as a repressor when tethered to a target reporter. The full-length
JMJD2A was fused to the Gal4 DNA binding domain (Gal-JMJD2A),
and repression was measured by cotransfection with the 4xUAS-TK-
luc reporter. The expression of Gal-JMJD2A was confirmed by West-
ern analysis, as shown at the bottom of panel. (C) Repression by
Gal-JMJD2A was correlated with recruitment of N-CoR and SMRT
corepressor complexes. HeLa cells were transfected with reporter
alone or reporter plus Gal(DBD) or Gal-JMJD2A, and, after over-
night incubation, ChIP assays were carried out to determine the re-
cruitment of SMRT and N-CoR and their associated HDAC3 to the
reporter.
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Identification of a JMJD2A interaction domain in N-CoR.
We next used an in vitro GST pulldown assay to test whether
JMJD2A directly interacts with N-CoR. A GST fusion con-
taining the JMJD2A N-CoR interaction domain was expressed
in E. coli and purified. This GST fusion (GST-472-720), to-
gether with control GST alone, was used to pull down in
vitro-translated, [35S]Met-labeled N-CoR, SMRT, HDAC3,
TBL1, and IR10, the components of the N-CoR/SMRT com-
plexes (50). The result in Fig. 4A showed that, among these
proteins, only N-CoR bound significantly to GST-472-720. This
result indicates that JMJD2A most likely interacts directly with
N-CoR but not other core subunits of N-CoR. Given that
SMRT was recruited by full-length JMJD2A in the ChIP assay
(Fig. 2C), the lack of SMRT binding in the GST pulldown
assay in Fig. 4A suggests that SMRT may interact with
JMJD2A through another unidentified region.
We further mapped the JMJD2A interaction domain in N-
CoR using a series of N-CoR constructs as indicated in Fig. 4C
by GST pulldown assay. The results in Fig. 4B showed that only
the N-terminal domain (amino acids 1 to 373), not other re-
gions of N-CoR, interacted with the N-CoR binding domain of
JMJD2A. Thus, we conclude that JMJD2A directly interacts
with the N-terminal fragment of N-CoR containing the previ-
ously identified repression domain 1 (RD1) (16).
With the knowledge that JMJD2A interacts with N-CoR
through a 41-amino-acid fragment from 597 to 637, we next
analyzed whether this interaction correlates with JMJD2A’s
repression activity. The result in Fig. 5A showed that fragment
1-370, containing the JmjC and JmjN domains, had no repres-
sion activity. To our satisfaction, the fragment containing the
N-CoR interaction domain (Gal-347-720) repressed transcrip-
tion from 4xUAS-TK-luc as efficiently as the full-length
JMJD2A. On the other hand, the C-terminal region containing
PHD and Tudor domains had a weaker but consistent repres-
sion activity. Since this region did not interact with N-CoR by
ChIP assay (Fig. 3A), we suggest that it may repress transcrip-
tion by interacting with another corepressor protein(s). We
also tested whether the N-CoR interaction domain of JMJD2A
alone was sufficient to repress transcription. The result in Fig.
5B showed that Gal-597-637 was able to repress transcription
as efficiently as the full-length JMJD2A. Interestingly, deletion
of the N-CoR interaction domain (Gal-597-637) did not sig-
nificantly affect its repression activity, presumably because
JMJD2A is capable of interacting with other corepressor pro-
teins (Fig. 5A).
Identification of ASCL2 as a JMJD2A target gene. Although
the Jumonji protein, a protein that also contains JmjC and
JmjN domains, can function as a DNA binding transcription
factor (26), JMJD2A does not appear to have a DNA binding
FIG. 3. Mapping the NID of JMJD2A to a small 41-amino-acid
NID region. (A to D) Various JMJD2A fragments as indicated were
fused to the Gal-DBD, and their ability to recruit N-CoR to the
4xUAS-TK-luc reporter was determined by ChIP assay. In each case,
a ChIP assay using a Gal-DBD-specific antibody was also performed to
confirm that each Gal fusion protein was expressed and bound to the
reporter. ChIP with IgG served as a negative control. JNID repre-
sents JMJD2A deleted of the NID fragment (amino acids 597 to 637).
(E) Summary of the interaction between various JMJD2A constructs
and N-CoR.
FIG. 4. JMJD2A directly interacts with N-CoR but not other sub-
units in the N-CoR complex. (A) A GST fusion of JMJD2A 472-720
containing the NID was expressed in E. coli and purified. Full-length
N-CoR, SMRT, HDAC3, TBL1, and IR10 proteins were individually
translated, [35S]Met labeled in vitro using the TNT transcription/trans-
lation kit, and used for GST pulldown assays. GST protein was in-
cluded as a negative control. (B) The N-CoR protein was divided into
five fragments, and binding to JMJD2A was analyzed by GST pull-
down as in panel A. (C) Diagram showing the five N-CoR fragments
used in panel B.
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domain based on sequence analysis. Based on the fact that
JMJD2A has the ability to recruit N-CoR and represses tran-
scription when tethered to a reporter, we hypothesized that
JMJD2A could function as a cofactor that mediates the inter-
action between unknown transcription factors and N-CoR, al-
though the possibility that JMJD2A possesses a sequence-
specific DNA binding activity could not been excluded. Given
its significant evolution conservation (24), we were specifically
interested in the identification of JMJD2A-regulated genes.
Toward this end, we used a ChIP cloning approach (45) to
identify DNA sequences in HeLa cells that were bound by both
JMJD2A and N-CoR. Specifically, HeLa cells were treated
with 1% formaldehyde to cross-link chromatin-associated pro-
teins with DNA. The chromatin was then sheared into 200- to
300-bp fragments by extensive sonication. The resulting chro-
matin fragments were immunoprecipitated with the JMJD2A
antibody, eluted, and reprecipitated with an N-CoR-specific
antibody. After reversal of cross-linking, DNA was purified,
blunt ended, and cloned. Among 80 clones sequenced, 76
clones were found to contain various repetitive sequences,
most likely reflecting their abundance in the genome and
therefore nonspecific. Among four clones with unique se-
quences, a clone was found to contain a 171-bp DNA fragment
that completely matched the sequence upstream of the human
ASCL2 gene transcriptional starting site (Fig. 6A). The other
three clones contained sequences very far away from known
transcription start sites and thus were not further pursued.
ASCL2 is a mammalian member of the achaete-scute family,
whose genes encode basic-helix-loop-helix transcription fac-
tors, and is strongly expressed in the extraembryonic tropho-
FIG. 5. Correlation of N-CoR interaction with transcriptional re-
pression activity of JMJD2A. (A) The ability of the N-terminal (Gal-
1-370), the middle (Gal-347-720), and C-terminal (Gal-680-1064) re-
gions of JMJD2A to repress transcription was analyzed by
cotransfection with a 4xUAS-TK-luc reporter. The repression activity
was compared to the control Gal-DBD (set as 1). Note that Gal-347-
720 containing the NID repressed transcription as effectively as the
full-length Gal fusion (Gal-JMJD2A). (B) The repression activity of
the 41-amino-acid NID alone (Gal-JNID) and JMJD2A deleted of the
NID (Gal-JNID) was analyzed as in panel A. Note that Gal-JNID
alone was able to repress transcription similarly to the full-length
JMJD2A. The Gal-JNID could also repress transcription, presum-
ably as a result of interacting with other corepressor protein(s). Ex-
periments in both panels A and B were repeated at least three times,
and the results were statistically significant (P  0.05).
FIG. 6. Identification of the ASCL2 gene as a JMJD2A-repressed
gene by ChIP cloning. (A) Gene structure of the human ASCL2 gene.
The 171-bp region identified by ChIP cloning is shown as the JAR.
(B) Knocking down JMJD2A in HeLa cells by siRNA led to increased
expression of ASCL2. HeLa cells were transfected with siRNA specific
for JMJD2A or a scrambled siRNA. Two days after transfection, cells
were collected and the levels of JMJD2A protein were analyzed by
Western blotting and the levels of ASCL2 mRNA were determined by
RT-PCR. SRC-3 served as a loading control for protein, and GAPDH
served as a control for RT-PCR. The RT-PCR was repeated at least
three times, and a representative result was quantified. The value for
the control was set as 1. (C) ChIP assays demonstrated the association
of JMJD2A and N-CoR with the ASCL2 distal promoter but not the
coding region. HeLa cells were first treated with the scrambled control
siRNA or siRNA against JMJD2A and processed for ChIP assays 2
days later. The antibodies used for ChIP assays were as indicated, and
rabbit anti-mouse IgG served as a negative control. DNA purified from
the ChIP assays was amplified with specific primers flanking either the
JAR or coding region. The experiments were repeated at least three
times, and a representative result was quantified. The value for the
control in each ChIP was set as 1.
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blast lineage (29, 31). The mouse ASCL2 gene is localized to
an imprinted region including the insulin-2 (INS-2), insulin-
like growth-factor 2 (IGF-2), and H19 genes on the distal end
of chromosome 7 (14). Furthermore, mouse ASCL2 is essen-
tial for adequate differentiation of the trophoblast (15). In
humans, the ASCL2/Hash2 gene has been mapped to 11p15.5,
a region corresponding to the imprinted region in mouse chro-
mosome 7 (30). In light of our ChIP cloning result, we next
focused on investigating whether ASCL2 is regulated by
JMJD2A and N-CoR.
To examine whether ASCL2 is regulated by JMJD2A, we
first designed siRNA specific for JMJD2A and established the
condition in which transfection of this siRNA substantially
knocked down JMJD2A level in HeLa cells (Fig. 6B), whereas
transfection of a control scramble siRNA had no effect. Con-
trol Western analysis using an SRC-3-specific antibody con-
firmed equal loading of the two samples (Fig. 6B). Under this
condition, we found that the expression level of the ASCL2
gene was significantly elevated in the HeLa cells transfected
with siRNA against JMJD2A. This result indicates that
JMJD2A is actively engaged in the repression of the ASCL2
gene.
We also performed ChIP assays to confirm that JMJD2A
binds specifically to the 171-bp fragment upstream of the
ASCL2 promoter identified by our ChIP cloning experiment.
To ensure that the signal derived from ChIP using JMJD2A
antibody is not nonspecific, we performed ChIP experiments
using HeLa cells treated with control siRNA or the JMJD2A-
specific siRNA. The results in Fig. 6C showed that both
JMJD2A and N-CoR could be detected on the ASCL2 pro-
moter from the control siRNA-treated cells. However, knock-
ing down JMJD2A by siRNA led to a substantial reduction of
the signal for JMJD2A, indicating that the ChIP signal indeed
reflected the binding of JMJD2A. Note that knocking down
JMJD2A by siRNA also led to a reduced association of N-
CoR, indicating that the association of N-CoR with the ASCL2
promoter is dependent on the presence of JMJD2A. Consis-
tent with the result that knocking down JMJD2A resulted in
elevated expression of ASCL2, a ChIP assay using an acety-
lated histone H3 antibody showed that the level of acetylated
histone H3 increased. In the same ChIP experiment, we found
that JMJD2A and N-CoR were not associated with the coding
region of the ASCL2 gene. Altogether, our RT-PCR and ChIP
data provide a working model that JMJD2A recruits the N-
CoR complex to the JMJD2A promoter region (presumably by
binding to the 171-bp DNA fragment) and represses ASCL2
gene expression, at least in part through histone deacetylation.
Repression by JMJD2A requires its tandem Tudor domain.
To further investigate the mechanism by which JMJD2A re-
presses ASCL2 gene expression, we cloned the ASCL2 pro-
moter region including the 171-bp fragment (referred as
JMJD2A-associated region [JAR]) that we identified in the
ChIP cloning into the pGL3-Basic vector (promoter-less lucif-
erase reporter). Using this reporter, we found that cotransfec-
tion of a JMJD2A expression construct resulted in dose-de-
pendent repression (Fig. 7A). To examine the role of the
171-bp JAR fragment in repression by JMJD2A, we made
three additional reporters with partial or complete deletion of
the JAR sequence (Fig. 7B, upper panel). By transient-trans-
fection experiments, we found that the repression by JMJD2A
was dependent on the presence of the 171-bp JAR fragment
identified by our ChIP cloning, because the reporter with this
fragment deleted was no longer sensitive to the repression by
JMJD2A (Fig. 7B, compare bars A and D). In addition, we
found that the first 79 bp of the 171-bp fragment was necessary
and sufficient to mediate repression of ASCL2 promoter by
JMJD2A (Fig. 7B, compare bars A and B), whereas deletion of
the first 64 bp from the reporter abolished the repression by
FIG. 7. Repression of the ASCL2 promoter by JMJD2A requires
the tandem Tudor domain of JMJD2A and is N-CoR dependent.
(A) JMJD2A repressed transcription driven by the ASCL2 promoter
in a dose-dependent manner. The ASCL2 promoter including the JAR
was cloned into the pGL3-basic reporter, and the ability of JMJD2A to
repress this reporter was assayed by transient transfection. The expres-
sion of JMJD2A is shown at the bottom of the panel by Western
blotting. (B) The first 79 bp of the JAR fragment is necessary and
sufficient to mediate repression by JMJD2A. The deletion reporter
constructs (bars B, C, and D) were cotransfected with or without
JMJD2A, and the relative level of repression was compared to the
ASCL2P-Luc reporter. The results were based on two independent
experiments. (C) The tandem Tudor domain of JMJD2A is essential
for its ability to repress transcription from the ASCL2P-Luc reporter.
HeLa cells were cotransfected with wild-type or mutant JMJD2A and
the ASCL2P-luc reporter. The relative luciferase activities from trip-
licates of two experiments are presented. (D) Knocking down N-CoR
or HDAC3 impaired repression by JMJD2A. HeLa cells were first
treated with siRNAs as indicated and 2 days later were transfected
with a JMJD2A expression construct and the ASCL2P-luc reporter.
The relative luciferase activities from triplicates of two experiments are
presented. The effect of siRNAs was confirmed by Western blotting
results shown in the lower panel.
6410 ZHANG ET AL. MOL. CELL. BIOL.
JMJD2A (Fig. 7B, compare bars A and C). Together, these
results provide strong evidence that JMJD2A binds directly or
indirectly to the first 79 bp of the 171-bp JAR fragment to
repress ASCL2 gene expression.
With the result that transfection of JMJD2A was sufficient to
repress transcription driven by the ASCL2 promoter contain-
ing the JAR fragment, we next wished to determine the func-
tional domain(s) of JMJD2A important for this repression. For
this deletion, we generated JMJD2A expression constructs de-
leting JmjN, PHD, or the tandem Tudor domains (Fig. 7C,
lower panel). The results in Fig. 7C showed that deletion of the
JmjN or PHD domain did not affect repression. However,
deletion of the tandem Tudor domain completely abolished its
repression activity. Western analysis confirmed the equal ex-
pression of the Tudor domain deletion mutant (data not
shown). Thus, we conclude that the tandem Tudor domain is
critically important for repression of the ASCL2 promoter by
JMJD2A.
Repression by JMJD2A is N-CoR and HDAC3 dependent.
We next investigated whether the ability for JMJD2A to re-
press the ASCL2 promoter-driven reporter was dependent on
N-CoR and its associated HDAC3. For this purpose, HeLa
cells were first transfected with the control scramble siRNA or
siRNA against JMJD2A, N-CoR, or HDAC3. Two days later,
the cells were transfected with the ASCL2P-luc reporter and
the JMJD2A expression plasmid. After overnight incubation,
cells were harvested for luciferase activity assay. The results in
Fig. 7D showed that, like siRNA against JMJD2A, siRNA
against N-CoR and HDAC3 also substantially relieved repres-
sion by JMJD2A. The Western analysis (Fig. 7D, lower panel)
confirmed the effect and specificity of each siRNA. Taken
together, we conclude that JMJD2A represses transcription
driven by the ASCL2 promoter in an N-CoR/HDAC3-depen-
dent manner.
JMJD2A is not required for repression by unliganded TR.
The above results suggest that both JMJD2A and N-CoR are
required for the repression of the ASCL2 gene. As a protein
that copurified with N-CoR, we next wished to investigate
whether JMJD2A is generally required for the repression func-
tion mediated by N-CoR. Toward this end, we compared the
effect of siRNA against JMJD2A and N-CoR on genes re-
pressed by unliganded TR, because the unliganded TR has
been extensively shown to repress transcription through N-
CoR. HeLa 	2 cells, which constitutively express human TR	1
(10), were used for this experiment. The result in Fig. 8A shows
that, while siRNA against N-CoR induced expression of
ADRE, a previously identified TR target gene (52), siRNA
against JMJD2A did not affect the expression of ADRE. On
the other hand, both siRNAs led to increased expression of
ASCL2, consistent with the result in Fig. 7 that both N-CoR
and JMJD2A are required for the repression of ASCL2 gene.
This result indicates that JMJD2A is not essential for N-CoR-
mediated repression by TR. In addition, this result is consistent
with the idea that JMJD2A is not a core subunit of the N-CoR
complex.
JMJD2A is not involved in the regulation of other imprinted
genes in human chromosome 11p15.5. Given that the ASCL2
gene is located in an imprinted region at human chromosome
11p15.5 containing the KCNQ1, IGF2, and H19 genes (1, 14)
(Fig. 8B), we next investigated whether JMJD2A is also in-
volved in the transcriptional regulation of these imprinted
genes. For this purpose, HeLa cells were treated with control
siRNA or siRNA against JMJD2A and the levels of IGF2 and
KCNQ1 were analyzed by RT-PCR. We expected that only the
maternal alleles of the IGF2 and KCNQ1 genes were ex-
pressed and paternal alleles of these genes silenced. We rea-
soned that the expression of IGF2 and KCNQ1 would be
enhanced if JMJD2A were involved in the imprinting of this
locus. The results in Fig. 8C revealed that knocking down
JMJD2A did not affect the expression levels of IGF2 and
KCNQ1 by quantitative PCR. However, as expected, knocking
down JMJD2A did lead to increased expression of ASCL2. In
addition, Western analysis using our JMJD2A-specific anti-
body confirmed knocking down of JMJD2A by its specific
siRNA. This result suggests that JMJD2A is specifically in-
volved in the regulation of the ASCL2 gene but not other
imprinted genes such as the IGF2 and KCNQ1 genes.
FIG. 8. JMJD2A is neither involved in regulation of imprinted
genes in 11p15.5 nor required for N-CoR-mediated repression of a TR
target gene. (A) Knocking down JMJD2A did not affect the repression
of TR target gene ADRE. As a positive control, knocking down N-
CoR resulted in increased expression of ADRE. The RT-PCR was
repeated three times, and a representative result was quantified. For
each gene, the value for the control was set as 1. (B) Ideogram of
human chromosome 11. The ASCL2 gene is mapped to 11p15.5, a
region of a cluster of imprinted genes: in order, a telomere (Tele) and
the H19, IGF2, INS2, ASCL2, and KCNQ1 genes. (C) The involve-
ment of JMJD2A in the expression of the imprinted KCNQ and IGF2
genes was assessed after knocking down JMJD2A by siRNA. Although
the level of ASCL2 mRNA increased, the levels of the KCNQ and
IGF2 genes did not change, as revealed by RT-PCR. The RT-PCR was
repeated twice, and a representative result was quantified. The value
for the control in each gene was set as 1. The knocking down of
JMJD2A was confirmed by Western analysis.
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DISCUSSION
Corepressor N-CoR and the highly related protein SMRT
play important roles in different biological processes including
proliferation, differentiation, and development. Although nu-
merous proteins (primarily transcription factors) have been
shown to interact with N-CoR by various approaches including
yeast and/or mammalian two-hybrid assays and in vitro and in
vivo interaction or functional assays (7, 11, 22, 23, 32, 33, 43,
44), biochemical purification of SMRT and N-CoR tends to
identify the proteins that associate stably and abundantly with
SMRT and N-CoR. Indeed, HDAC3, GPS2, TBL1, and
TBLR1 were all identified based on biochemical purification
and considered as the core subunits of the SMRT/N-CoR
complexes (13, 27, 50, 51, 53). Additional proteins identified by
a biochemical approach that are abundantly associated with
N-CoR include the methyl CpG binding protein Kaiso and the
actin-binding protein IR10 (50, 51). Here we show that
JMJD2A interacts directly with N-CoR, associates with only a
fraction of N-CoR, and is not generally required for repression
by N-CoR. In this regard, JMJD2A represents the first bio-
chemically identified N-CoR interacting protein that is not
abundantly associated with N-CoR.
Besides its copurification with N-CoR, we present both in
vitro and in vivo evidence that JMJD2A interacts with N-CoR.
First, JMJD2A and N-CoR could be reciprocally coimmuno-
precipitated (Fig. 1B and C). Second, a fraction of JMJD2A in
HeLa nuclear extracts was found to cofractionate with N-CoR
in gel filtration analysis (Fig. 1D). Third, tethering JMJD2A to
a reporter DNA resulted in recruitment of the N-CoR complex
and repression of transcription (Fig. 2). Finally, JMJD2A in-
teracted with N-CoR in in vitro pulldown assays (Fig. 4). By
using a combination of in vitro and in vivo interaction assays,
we were able to map the N-CoR interaction domain (NID) to
a small 41-amino-acid region in the middle portion of JMJD2A
and the JMJD2A interaction to the N-terminal RD1 region of
N-CoR. Interestingly, the NID region is enriched with acidic
amino acids, suggesting that its interaction with N-CoR may be
electrostatically dependent. In addition, the NID region is not
as evolutionarily conserved as other noticeable domains such
as the JmjN, JmjC, PHD, and Tudor domains in JMJD2A.
Nevertheless, this small region is highly conserved among
higher eukaryotic cells (our unpublished data). Thus, it is pos-
sible that only in higher eukaryotic cells does JMJD2A make
use of N-CoR complexes for repression of its target gene
expression.
Despite strong evidence that JMJD2A copurifies and inter-
acts with N-CoR, JMJD2A is unlikely a core subunit of the
N-CoR complex for the following reasons. First, only a small
fraction of JMJD2A was found to cofractionate with N-CoR in
gel filtration experiments and much of the JMJD2A behaved
as free protein (Fig. 1D). Under the same conditions, HDAC3,
TBL1, and TBLR1 were previously shown to cofractionate
extensively with N-CoR and SMRT. Second, although
JMJD2A and N-CoR could be coimmunoprecipitated (Fig. 1B
and C), we could not deplete N-CoR from HeLa nuclear ex-
tracts with our JMJD2A-specific antibody and vice versa. This
is in contrast to the cases of core subunits such as HDAC3,
TBL1, and Kaiso, whose codepletion with N-CoR from HeLa
nuclear extracts with their specific antibodies was shown pre-
viously (27, 51). Third, JMJD2A was not required for N-CoR-
mediated repression of TR target genes (Fig. 8C). On the
other hand, JMJD2A repressed the ASCL2 promoter-driven
transcription in an N-CoR complex-dependent manner (Fig. 7
and 8). Altogether, our data indicate that JMJD2A is unlikely
a core subunit of the N-CoR complex but represses transcrip-
tion by making use of the N-CoR complex.
As shown in Fig. 1A, the JMJD2A protein contains several
well-conserved domains including the JmjN and JmjC domains
in the N terminus and the PHD and Tudor domains in the C
terminus. The function of each of these domains is not well
understood. The JmjC and JmjN domains have been identified
in over 100 eukaryotic and bacterial proteins, including several
putative chromatin-associated proteins, especially the jumonji
family of eukaryotic transcription factors (6). Although the
proteins containing JmjC and JmjN domains are generally
believed to be metalloenzymes, the mammalian jumonji family
proteins including JMJD2A are predicted to be enzymatically
inactive because of the lack of a few key conserved amino acids
in this domain that are necessary for enzymatic activity (6).
Recent studies show that the Jumonji, a member of the JMJD2
family proteins, can regulate transcription either as a se-
quence-specific DNA binding transcription factor or by inhib-
iting other transcription factor activity (25, 26). However, by
using either in vitro-translated JMJD2A or JMJD2A purified
from mammalian cells, we have not been able to detect a direct
binding of JMJD2A protein to the 171-bp fragment upstream
of the ASCL2 promoter by gel mobility shift assay (data not
shown). A close comparison of the Jumonji transcription factor
and JMJD2A revealed that the sequence involved in DNA
binding of Jumonji is not present in JMJD2A. Thus, although
JMJD2A is capable of repressing both endogenous ASCL2
(Fig. 6) and a transfected luciferase reporter driven by the
ASCL2 promoter (Fig. 7), JMJD2A may not bind directly to
the 171-bp fragment and its repressive effect may be mediated
through another transcription factor(s) that binds to this frag-
ment. To look for the putative transcription factor(s) that
mediates JMJD2A action, we have analyzed the potential tran-
scription factor binding sites in the 171-bp JAR fragment (our
unpublished data) by using the Consite program with a cutoff
of 80% (http://mordor.cgb.ki.se/cgi-binl). According to this
program, the first 79 bp of the JAR region may contain binding
sites for nuclear factor Y (NF-Y), repressor snail, E74A, and
Ets family member ELF-2. Future work will test if NF-Y, snail,
and ELF-2 interact directly with JMJD2A.
Tudor and its related domains have been identified in many
proteins (28). Recent studies on the Tudor domain of the
“survival of motor neurons” protein (SMN) indicate that it is
required for interaction with the spliceosomal Sm proteins.
Specifically, the Tudor domain of SMN interacts with symmet-
rically dimethylated arginine residues in an RG-rich region of
Sm proteins (5, 38, 46). In addition, a recent report showed
that the tandem Tudor domain of mammalian checkpoint pro-
tein 53BP1 binds specifically to lysine 79-methylated histone
H3 and plays a role in double-strand DNA break repair (19).
Interestingly, methylation of histone H4 lysine 20 in yeast con-
trols recruitment of Crb2, the yeast homolog of 53BP1, to sites
of DNA damage, although it is yet to be demonstrated whether
Crb2 binds directly to the lysine 20-methylated H4 (37). In this
study, we show that the tandem Tudor domain of JMJD2A is
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required for JMJD2A to repress the ASCL2 gene promoter
(Fig. 7C). It is possible that the tandem Tudor domain medi-
ates the interaction of JMJD2A with the putative transcription
factor(s) that binds to the ASCL2 promoter.
The identification of the ASCL2 gene as a gene regulated by
JMJD2A and N-CoR is of biological significance. The ASCL2
gene encodes a basic helix-loop-helix transcriptional factor.
Mouse ASCL2, also called Mash2, is required for embryonic
development due to its essential role in placental development
(15). This placental mutant phenotype can be rescued by con-
structing chimeras with tetraploid wild-type embryos which
provide extraembryonic tissues. Under this condition, the
Mash2/ embryos developed normally and adult Mash2/
mice were viable, demonstrating that Mash2 has no major role
in the embryo itself (15). Interestingly, expression of the
ASCL2 gene is tightly regulated and tissue specific. Both
mouse and human ASCL2s are only strongly expressed in the
extraembryonic trophoblast lineage but repressed in other tis-
sues (1, 15, 31). Given our data that JMJD2A represses ASCL2
expression and that both JMJD2A and N-CoR are broadly
expressed in various mouse tissues (Fig. 1E), we suggest that
JMJD2A and N-CoR could contribute to the restricted expres-
sion of ASCL2.
The mouse ASCL2 gene is located to the distal region of
chromosome 7 within a cluster of imprinted genes, including
the KCNQ1, IGF2, and H19 genes (14). The human ASCL2
gene is mapped to chromosome 11p15.5 (1, 30), the region
syntenic with mouse chromosome 7, indicating that this im-
printed region is highly conserved in evolution. Although the
ASCL2 gene in mice is clearly an imprinted gene, human
ASCL2 may escape imprinting (29). Nevertheless, our data
that JMJD2A and N-CoR are involved in repression of ASCL2
raise the question as to whether JMJD2A and N-CoR could
also affect other imprinted genes in the region. Since knocking
down JMJD2A had little effect on KCNQ1 and IGF2 expres-
sion, whereas the same treatment released the repression of
the ASCL2 gene (Fig. 8), it is unlikely that JMJD2A and
N-CoR are involved in the regulation of the gene imprinting.
Together, our data are consistent with a previous study show-
ing that the allele-specific chromatin configuration could be
involved in the transcriptional repression of mouse Mash2
within the imprinted cluster (41). It will be interesting to de-
termine whether JMJD2A and N-CoR are involved in im-
printed expression of Mash2 in mice in the future.
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